CT-P13 SC Auto-injector

BIOLOGICAL2 trials

Sponsors

Celltrion

Conditions

Health, SubjectiveModerately to Severely Active Rheumatoid Arthritis

Phase 1

CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects

CompletedNCT03446976

CelltrionHealth, Subjective

Start: 2018-02-21End: 2018-07-26Updated: 2019-07-26

Phase 3

A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis

CompletedNCT06738719

CelltrionModerately to Severely Active Rheumatoid Arthritis

Start: 2025-01-03End: 2026-04-13Updated: 2026-04-23

Related Papers

DOP010 Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics–pharmacodynamics study

Journal of Crohn s and Colitis2025-01-01